Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials

25 Aug 2025

Abstract excerpt

INTRODUCTION: (CRAB) infections have become common in healthcare settings worldwide, yet current therapeutic options are limited. A pipeline of new antibiotics and non-traditional antimicrobial agents is being developed to address the urgent need for efficacious therapeutic options for patients with CRAB infections. AREAS COVERED: -327, xeruborbactam/QPX-7728, upleganan/SPR-206, MRX-8, QPX-9003,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Bacteriophages and microbial interactions
Share to Burkholderia infections and melioidosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40851518
DOI: 10.1080/13543784.2025.2552846

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trialsPMID 40851518Read ↗

Zosurabalpin: an antibiotic with a new mechanism of action against carbapenem-resistant Acinetobacter baumanniiSemantic proximity Read ↗

Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and InnovationsSemantic proximity Read ↗

A novel antibiotic class targeting the lipopolysaccharide transporterSemantic proximity Read ↗

Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?Semantic proximity Read ↗

Nonribosomal antibacterial peptides that target multidrug-resistant bacteriaSemantic proximity Read ↗

Antimicrobial resistance during COVID-19 pandemic: alternatives to combat bacterial infections.Semantic proximity Read ↗

Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistant Acinetobacter baumannii tested in the Antimicrobial Resistance Laboratory Network—United States, 2017–2020Semantic proximity Read ↗

An Update of Peptides With Therapeutic Potential Against <em>Acinetobacter baumannii </em>InfectionsSemantic proximity Read ↗

Development of Antimicrobial Agents in the Era of New and Reemerging Infectious Diseases and Increasing Antibiotic ResistanceSemantic proximity Read ↗

Current and novel therapies for management of Acinetobacter baumannii -associated pneumoniaSemantic proximity Read ↗

In Vivo Application of Bacteriophage as a Potential Therapeutic Agent To Control OXA-66-Like Carbapenemase-Producing Acinetobacter baumannii Strains Belonging to Sequence Type 357.Semantic proximity Read ↗

Developments on antibiotics for multidrug resistant bacterial Gram-negative infectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.